NCCN Guidelines Updates: Breast Cancer

Restricted access

Advances in molecular testing have ushered in the new era of precision medicine. The 2018 publication of the TAILORx trial helped refine the use of genetic expression assays, specifically the 21-gene recurrence score, in assigning patients to endocrine therapy alone or with chemotherapy. The NCCN Guidelines for Breast Cancer explore the clinical applications of this study. The algorithm for managing the axilla in early breast cancer has been further refined, based on the presence or absence of clinical evidence of lymph node involvement. Ovarian suppression has been validated as the optimal approach in higher risk premenopausal women, based on updated analysis of the SOFT and TEXT pivotal trials. In the metastatic setting, the NCCN Guidelines further reinforce the benefit of the CDK4/6 inhibitors, extending the “preferred” recommendation to all the available agents in metastatic disease. Options in triple-negative breast cancer now include, for the first time, an immunotherapeutic agent.

Correspondence: Melinda L. Telli, MD, Stanford Cancer Institute, 875 Blake Wilbur Drive, MC 5820, Stanford, CA 94305-5826. Email: mtelli@stanford.edu; William J. Gradishar, MD, Robert H. Lurie Comprehensive Cancer Center of Northwestern University, 676 North St. Clair Street, Suite 850, Chicago IL 60611. Email: w-gradishar@northwestern.edu; and John H. Ward, MD, Huntsman Cancer Institute at the University of Utah, 2000 Circle of Hope, Salt Lake City, UT 84132. Email: john.ward@hci.utah.edu
  • 1.

    Sparano JA, Gray RJ, Makower DF, . Adjuvant chemotherapy guided by a 21-gene expression assay in breast cancer. N Engl J Med 2018;379:111–121.

  • 2.

    Francis PA, Pagani O, Fleming GF, . Tailoring adjuvant endocrine therapy for premenopausal breast cancer. N Engl J Med 2018;379:122–137.

  • 3.

    Giuliano AE, Ballman K, McCall L, . Locoregional recurrence after sentinel lymph node dissection with or without axillary dissection in patients with sentinel lymph node metastases: long-term follow-up from the American College of Surgeons Oncology Group (Alliance) ACOSOG Z0011 randomized trial. Ann Surg 2016;264:413–420.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 4.

    Hurvitz SA, Andre F, Jiang Z, . Combination of everolimus with trastuzumab plus paclitaxel as first-line treatment for patients with HER2-positive advanced breast cancer (BOLERO-1): a phase 3, randomised, double-blind, multicentre trial. Lancet Oncol 2015;16:816–829.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 5.

    Giridhar KV, Choong GM, Leon-Ferre RA, . Clinical management of metastatic breast cancer after CDK4/6 inhibitors: a retrospective single-institution study [abstract]. Presented at the 2018 San Antonio Breast Cancer Symposium, December 4–8, 2018; San Antonio, Texas. Abstract P6-18-09.

    • Export Citation
  • 6.

    André F, Ciruelos EM, Rubovszky G, . Alpelisib + fulvestrant for advanced breast cancer: results of the phase 3 SOLAR-1 trial. Presented at the 2018 ESMO Congress, October 19–23, 2018; Munich, Germany.

    • Search Google Scholar
    • Export Citation
  • 7.

    Juric D, Ciruelos EM, Rubovszky G, . Alpelisib + fulvestrant for advanced breast cancer: phase 3 SOLAR-1 trial results [abstract]. Presented at the 2018 San Antonio Breast Cancer Symposium, December 4–8, 2018; San Antonio, Texas. Abstract GS3-08.

    • Export Citation
  • 8.

    Robson M, Im SA, Senkus E, . Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. N Engl J Med 2017;377:523–533.

  • 9.

    Litton JK, Rugo HS, Ettl J, . A phase 3 trial comparing talazoparib, an oral PARP inhibitor, to physician’s choice of therapy in patients with advanced breast cancer and a germline BRCA mutation [abstract]. Presented at the 2017 San Antonio Breast Cancer Symposium, December 5–9, 2017; San Antonio, Texas. Abstract GS6-07.

    • Export Citation
  • 10.

    Schmid P, Adams S, Rugo HS, . Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer. N Engl J Med 2018;379:2108–2121.

All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 4548 4548 312
PDF Downloads 2060 2060 117
EPUB Downloads 0 0 0